Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and type 2 diabetes status (Abstract 10506).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007).
Christine Lovly, MD, PhD, FASCO, of City of Hope, offers her thoughs on the findings of the LIBRETTO-432 trial, which found improved event-free survival with adjuvant selpercatinib after definitive therapy for patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC) (Abstract LBA3).
Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and preliminary efficacy for elacestrant and capivasertib for patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer who experienced disease progression on first-line endocrine therapy plus CDK4/6 inhibition (Abstract 1098).
Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation therapy vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer. Dr. Kibel talks about how the regimen of apalutamide and ADT affects both the surgical procedure itself as well as patient outcomes postprocedure (Abstract LBA1).
